ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO1438

Peripheral Administration of 3% Sodium Chloride Is Not Associated with Local Infusion Reactions

Session Information

Category: Fluid, Electrolyte, and Acid-Base Disorders

  • 902 Fluid, Electrolyte, and Acid-Base Disorders: Clinical

Authors

  • Moritz, Michael L., University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
  • Ayus, Juan Carlos, Renal Consultants of Houston, Houston, Texas, United States
  • Nelson, Joel B., University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Background

Three-percent sodium chloride (3% NaCl) is a hyperosmolar agent indicated for the treatment of hyponatremic encephalopathy or to raise the serum osmolality in other cases of increased intracranial pressure. A barrier to the use of 3% NaCl is the perceived risk of a local infusion reactions when administered through a peripheral vein (Front Med. 2019 Mar 15;6:47), even though it has not been reported in large case series of 3% NaCl (AJKD. 2015 Mar;65(3):435-42). We sought to evaluate reports of local infusion reactions associated with 3% NaCl over a 10-year-period throughout a large healthcare system.

Methods

A query was conducted through Risk Master database to determine if there were any local infusion reactions associated with peripheral 3% NaCl administration throughout the entire UPMC health system over a 10-year time period from May 14, 2010 to May 14, 2020. Search terms included infiltrations, extravasations, phlebitis, IV site issues and IV solutions.

Results

In over 1.1 million events (figure), there were 23,714 intravenous events which were non-chemotherapeutic or non-contrast of which 4,648 (19.7%) were in children. 617 (2.59%) of these events were deemed serious by a patient safety officer. There were no reported local infusion reactions with 3% NaCl.

Conclusion

There were no reported local infusion reactions events associated with 3% NaCl in a large healthcare system despite widespread use of 3% NaCl and numerous intravenous events reported. This suggests that 3% NaCl can be safely administered through a peripheral IV.

Local Intravenous Infusion Reactions